Business News

GSK kills major vaccine vaccine in Pfizer

GlaxoSmithKline steals major vaccine from Pfizer, with UK pharmacist betting on the future of mRNA technology.

Philip Dormitzer this week he joined GSK as a global leader in vaccine research and development, leaving the company to play a key role in the development of Pfizer’s Covid-19 vaccine, as well as to help form a partnership with BioNTech.

He led a U.S. vaccine team developing a virus vaccine, including his work on influenza mRNA vaccine and BioNTech, and overseeing the syncytial virus vaccine, which will compete with GSK’s growing rifle. Pfizer did not respond to a request for comment.

Hal Barron, GSK’s chief science officer, said he was “delighted” to receive Dormitzer and “essential” in mRNA and other technologies, noting that recruitment was crucial for GSK’s continued credibility. vaccine leader.

“The need for vaccines has not always been clear, and the pace of technical expertise has not been greater,” he said.

GSK is left behind at the Covid jab competition. Instead of making it his own, it provided an “adjuvant” to increase the effectiveness of various other vaccines, including the one made by French pharmacist Sanofi. But after a going back to previous trials, Sanofi and GSK have not yet released the results of phase 3 for vaccine seekers.

A UK-based pharmaceutical retailer is investing heavily in mRNA technology, including the German alliance biotech CureVac in its second Covid launch.

Dame Emma Walmsley, GSK executive director, encountered questions about the lack of scientific expertise while trying reviving the company’s drug pipeline. Sponsors Elliott Management and Bluebird Capital Partners have taken part in pushing for a radical change in the organization, ahead of the start of its health business planning next year.

Dormitzer will help promote GSK’s high-tech scientific team and demonstrate that the company is committed to developing vaccines. Several vaccine officials have left GSK this year to partner with smaller companies, including Amin Khan, who went to GreenLight Biosciences, Emmanuel Hanon, who joined Viome, and Amir Reichman, who now leads BiondVax Pharmaceuticals.

Roger Connor, President of Global Vaccination at GSK, told the Financial Times that the epidemic had helped to confirm the technical importance of mRNA.

“We are investing heavily behind this, we have 200 scientists working on mRNA, and this does not include CureVac scientists, [and] we are developing an mRNA vaccine, “he said.


Source link

Related Articles

Leave a Reply

Back to top button